Drugs Made In America Acquisition (DMAAU) Operating Expenses (2025)

Drugs Made In America Acquisition (DMAAU) reported Operating Expenses of $2.1 million for Q4 2025, up 692.36% quarter-over-quarter from $263703.0 in Q3 2025.

Drugs Made In America Acquisition (DMAAU) Operating Expenses (2025) Analysis & Trends

Drugs Made In America Acquisition has reported Operating Expenses for 1 years, with the latest figure at $2.1 million in Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses changed N/A year-over-year to $2.1 million; the trailing twelve-month figure through Dec 2025 stood at $2.8 million (changed N/A YoY), and the FY2025 full-year result was $2.8 million, up 906.28% from the prior year.
  • Operating Expenses for Q4 2025 stood at $2.1 million, up from $263703.0 in the prior quarter.
  • The five-year high for Operating Expenses was $2.1 million in Q4 2025, with the low at $131919.0 in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Opex (Qtr)
1 EQV Ventures Acquisition 477.69 Mn 477.69 Mn - 427,850.00
2 Berto Acquisition 312.46 Mn 312.46 Mn - 482,100.00
3 Centurion Acquisition 311.65 Mn 311.65 Mn - 201,744.00
4 GP-Act III Acquisition 311.36 Mn 311.36 Mn - 84,204.00
5 Churchill Capital Corp IX 310.79 Mn 310.79 Mn - 1.15 Mn
6 WEN Acquisition 309.15 Mn 309.15 Mn - 225,545.00
7 Bold Eagle Acquisition 275.54 Mn 275.54 Mn - 198,194.00
8 Soulpower Acquisition 264.91 Mn 264.91 Mn - 685,558.00
9 BTC Development 262.16 Mn 262.16 Mn - 540,761.00
10 Drugs Made In America Acquisition - - - 2.09 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 2.09 Mn
Sep 30, 2025 263,703.00
Jun 30, 2025 131,919.00
Mar 31, 2025 330,925.00